Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strains

Haobam, Reena; Sindhu, Kizhakke M.; Chandra, Goutam; Mohanakumar, Kochupurackal P.

doi:10.1016/j.bbr.2005.04.011

Cited by 93 publications

(61 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Akinesia was measured by recording the latency (in seconds) of the animals to move all four limbs, and the test was terminated when the latency exceeded 180 sec (19).…”

Section: Stem Cells Isolationmentioning

confidence: 99%

“…The term catalepsy indicates the inability of rodents to correct an externally imposed posture (19). It was measured by placing the animals on a flat horizontal surface with the two hind limbs on a square wooden block (3-cm high), and the latency to move the hind limbs from the block to the ground was estimated in seconds.…”

Section: Stem Cells Isolationmentioning

confidence: 99%

“…Subsequently, TH immunostained brain sections were evaluated as follows: i) Striatal TH-fiber density measurement was performed using Image J software (http://imagej.nih.gov/ij/) as previously described (19); and ii) number of dopaminergic neurons in the SNpc were counted as previously described (20), and were reported as percentages of the control neurons (with the control set to 100%).…”

Section: Stem Cells Isolationmentioning

confidence: 99%

See 2 more Smart Citations

Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease

Salama

Sobh

Emam

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. It affects the locomotor system, leading to a final severe disability through degeneration of dopaminergic neurons. Despite several therapeutic approaches used, no treatment has been proven to be effective; however, cell therapy may be a promising therapeutic method. In addition, the use of the intranasal (IN) route has been advocated for delivering various therapies to the brain. In the present study, the IN route was used for administration of mesenchymal stem cells (MSCs) in a mouse model of PD, with the aim to evaluate IN delivery as an alternative route for cell based therapy administration in PD. The PD model was developed in C57BL/6 mice using intraperitoneal rotenone administration for 60 consecutive days. MSCs were isolated from the mononuclear cell fraction of pooled bone marrow from C57BL/6 mice and incubated with micrometer-sized iron oxide (MPIO) particles. For IN administration, we used a 20 µl of 5x10 5 cell suspension. Neurobehavioral assessment of the mice was performed, and after sacrifice, brain sections were stained with Prussian blue to detect the MPIO-labeled MSCs. In addition, immunohistochemical evaluation was conducted to detect tyrosine hydroxylase (TH) antibodies in the corpus striatum and dopaminergic neurons in the substantia nigra pars compacta (SNpc). The neurobehavioral assessment revealed progressive deterioration in the locomotor functions of the rotenone group, which was improved following MSC administration. Histopathological evaluation of brain sections in the rotenone+MSC group revealed successful delivery of MSCs, evidenced by positive Prussian blue staining. Furthermore, rotenone treatment led to significant decrease in dopaminergic neuron number in SNpc, as well as similar decrease in the corpus striatum fiber density. By contrast, in animals receiving IN administration of MSCs, the degeneration caused by rotenone treatment was significantly counteracted. In conclusion, the present study validated that IN delivery of MSCs may be a potential safe, easy and cheap alternative route for stem cell treatment in neurodegenerative disorders.

show abstract

“…Akinesia was measured by recording the latency (in seconds) of the animals to move all four limbs, and the test was terminated when the latency exceeded 180 sec (19).…”

Section: Stem Cells Isolationmentioning

confidence: 99%

Section: Stem Cells Isolationmentioning

confidence: 99%

Section: Stem Cells Isolationmentioning

confidence: 99%

See 1 more Smart Citation

Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease

Salama

Sobh

Emam

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Degeneration of nigrostriatal structures was associated with motor dysfunction while bilateral lesions in the nigrostriatal system produce akinesia, rigidity and catalepsy [49]. There was a high degree of correlation between dopaminergic neuron degeneration and motor impairment in MPTP-induced Parkinsonism model [49].…”

Section: Discussionmentioning

confidence: 99%

“…There was a high degree of correlation between dopaminergic neuron degeneration and motor impairment in MPTP-induced Parkinsonism model [49]. Measurement of motor activity in experimental Parkinsonism models depends on the performance of animals in well defined tasks.…”

Section: Discussionmentioning

confidence: 99%

Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease

Hacioglu

Seval-Celik

Tanrıöver

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Docosahexaenoic acid (DHA), a major polyunsaturated fatty acid (PUFA) in the phospholipid fraction of the brain, is essential for normal cellular function. Neurodegenerative disorders such as Parkinson's disease (PD) often exhibit significant declines in PUFAs. The aim of this study was to observe the effects of DHA supplementation in an experimental rat model of PD created with '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine' (MPTP). Adult male Wistar rats were divided into four groups: (1) Control; (2) DHA-treated; (3) MPTP-induced; and (4) MPTP-induced + DHA-treated. Motor activity was investigated using the 'vertical pole' and 'vertical wire' tests. The dopaminergic lesion was determined by immunohistochemical analysis for tyrosine hydroxylase (TH)-immunopositive cells in substantia nigra (SN). Immunoreactivities of Bcl-2, Akt and phosphorylated-Akt (p-Akt) in SN were evaluated by immunohistochemistry. MPTP-induced animals exhibited decreased locomotor activity, motor coordination and loss of equilibrium. Diminished Parkinsonism symptoms and decreased dopaminergic neuron death were detected in the MPTP-induced + DHA-treated group compared to the MPTP-induced group. Moderate decreases in Akt staining were found in the MPTP-induced and MPTP-induced + DHA-treated groups compared to controls. p-Akt immunoreactivity decreased dramatically in the MPTP-induced group compared to the control; however, it was increased in the MPTP-induced + DHA--treated group compared to the MPTP-induced group. The staining intensity for Bcl-2 decreased prominently in the MPTP-induced group compared to the control, while it was stronger in the MPTP-induced + DHA-treated group compared to the MPTP-induced group. In conclusion, DHA significantly protects dopaminergic neurons against cell death in an experimental PD model. Akt/p-Akt and Bcl-2 pathways are related to this protective effect

show abstract

Epalrestat improves motor symptoms by reducing oxidative stress and inflammation in the reserpine induced mouse model of Parkinson’s disease

Rahman

Chakraborti

Potol

et al. 2019

Anim Models and Exp Med

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting a large number of elderly people worldwide. The current therapies for PD are symptom-based; they do not provide a cure but improve the quality of life. Muscular dysfunction is the hallmark clinical feature of PD and oxidative stress and inflammation play a critical role in its pathogenesis. Epalrestat is used for the treatment of diabetic neuropathy and is known to improve antioxidative defense mechanisms in the CNS. Therefore, in this study, we investigated the role of Epalrestat in the reserpine induced mouse model of PD. Method:We used Swiss Albino mice for the PD model and tested for akinesia/bradykinesia, muscular rigidity, palpebral ptosis, and tremor, as well as conducting swim and open field tests. Brain samples were used to determine oxidative stress parameters and infiltration of immune cells. Results:Epalrestat treatment significantly improved akinesia and bradykinesia, muscular dysfunctions, tremor level, and gait functions compared to the reserpine group. It also improved the latency in the swim test. Eplarestat significantly reduced lipid peroxidation and NO concentration in different brain tissues and increased the activity of antioxidative enzymes, glutathione, catalase, and superoxide dismutase.Furthermore, Epalrestat reduced neuroinflammation by reducing the number of infiltrating immune cells. Conclusion:Eplarestat improves muscular dysfunction in PD by reducing oxidative stress and inflammation. K E Y W O R D Sbradykinesia, Epalrestat, glutathione, oxidative-stress, Parkinson's disease

show abstract

Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strains

Cited by 93 publications

References 46 publications

Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease

Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease

Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease

Epalrestat improves motor symptoms by reducing oxidative stress and inflammation in the reserpine induced mouse model of Parkinson’s disease

Contact Info

Product

Resources

About